Related Experiment Video
Updated: Feb 16, 2026
Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
Published on: February 18, 2020
CDKN2A and CDKN2B methylation in coronary heart disease cases and controls
Jinyan Zhong1,2, Xiaoying Chen3, Huadan Ye3
1Cardiology Center, Ningbo First Hospital, Ningbo University, Ningbo, Zhejiang 315010, P.R. China.
Abstract:
The aim of the present study was to investigate the association between cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent kinase inhibitor 2B (CDKN2B) methylation, and coronary heart disease (CHD), and to explore the interaction between methylation status and CHD clinical characteristics in Han Chinese patients. A total of 189 CHD (96 males, 93 females) and 190 well-matched non-CHD controls (96 males, 94 females) were recruited for the study. Methylation-specific polymerase chain reaction technology was used to examine gene promoter methylation status. Comparisons of methylation frequencies between CHD and non-CHD patients were carried out using the Chi-square test. Methylation levels of CDKN2A and CDKN2B genes were not found to be associated with the risk of CHD. However, the mean age of CDKN2A-hypermethylated participants was significantly lower than CDKN2A-unmethylated participants (58.73±5.88 vs. 62.62±5.36 years, adjusted P<0.001). Conversely, the mean age of CDKN2B-hypermethylated participants was significantly higher compared with CDKN2B-unmethylated participants (62.26±5.48 vs. 58.33±7.47 years, adjusted P=0.048). In addition, CDKN2B methylation frequencies were significantly increased in female participants compared with males (99.47 vs. 11.98%, P=0.032). In conclusion, the results indicated that CDKN2A and CDKN2B promoter methylation frequencies were significantly associated with age, and there was a gender dimorphism in CDKN2B methylation.
Insights
Investigating cyclin-dependent kinase inhibitor 2A (CDKN2A) and 2B (CDKN2B) methylation in coronary heart disease (CHD), this study found no direct link to CHD risk. However, methylation status correlated significantly with participant age and showed gender differences in CDKN2B.
Area of Science:
- Epigenetics
- Cardiovascular Disease Research
- Human Genetics
Background:
- Coronary heart disease (CHD) is a significant global health concern.
- Gene promoter methylation, an epigenetic mechanism, plays a role in various diseases.
- The roles of CDKN2A and CDKN2B methylation in CHD pathogenesis require further investigation.
Purpose of the Study:
- To investigate the association between CDKN2A and CDKN2B gene promoter methylation and CHD.
- To explore potential interactions between methylation status and clinical characteristics of CHD.
- To analyze methylation patterns in Han Chinese patients with and without CHD.
Main Methods:
- Study included 189 CHD patients and 190 non-CHD controls.
- Methylation-specific polymerase chain reaction (PCR) technology was employed.
- Chi-square tests were used for statistical comparisons of methylation frequencies.
Main Results:
- No significant association was found between CDKN2A/CDKN2B methylation levels and CHD risk.
- CDKN2A hypermethylation was associated with lower mean participant age (P<0.001).
- CDKN2B hypermethylation was associated with higher mean participant age (P=0.048) and increased frequency in females (P=0.032).
Conclusions:
- CDKN2A and CDKN2B promoter methylation frequencies are significantly associated with age.
- A notable gender dimorphism exists in CDKN2B methylation patterns.
- Further research is needed to elucidate the precise role of these epigenetic modifications in cardiovascular health.
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:27Coronary Artery Disease V: Interprofessional Care
01:23Rheumatic Heart Disease I: Introduction
01:30Coronary Artery Disease III: Clinical Manifestations
01:26Coronary Artery Disease IV: Preventive Measures